Vertex Pharmaceuticals Inc. (VRTX)

177.66
2.49 1.38
NASDAQ : Health Technology
Prev Close 180.15
Open 180.11
Day Low/High 177.13 / 181.03
52 Wk Low/High 145.37 / 195.81
Volume 765.90K
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 256.12M
Market Cap 46.36B
EPS 8.20
P/E Ratio 21.78
Div & Yield N.A. (N.A)

Latest News

Vertex To Present Data At ECFS Conference On Potential Impact Of Early Treatment And Long-Term Treatment With CFTR Modulators On The Underlying Cause Of CF

Vertex To Present Data At ECFS Conference On Potential Impact Of Early Treatment And Long-Term Treatment With CFTR Modulators On The Underlying Cause Of CF

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from six scientific abstracts from the company's portfolio of cystic fibrosis (CF) medicines will be presented at the 42 nd European Cystic Fibrosis Conference, taking place June...

Vertex Selects Triple Combination Regimen Of VX-445, Tezacaftor And Ivacaftor To Submit For Global Regulatory Approvals In Cystic Fibrosis

Vertex Selects Triple Combination Regimen Of VX-445, Tezacaftor And Ivacaftor To Submit For Global Regulatory Approvals In Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has selected the triple combination of the next-generation corrector VX-445 (elexacaftor), tezacaftor and ivacaftor to submit for potential global regulatory approvals for people...

Vertex And Kymera Therapeutics Establish Strategic Collaboration To Discover And Develop Targeted Protein Degradation Medicines For Serious Diseases

Vertex And Kymera Therapeutics Establish Strategic Collaboration To Discover And Develop Targeted Protein Degradation Medicines For Serious Diseases

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Kymera Therapeutics today announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple...

Noteworthy Friday Option Activity: VRTX, AAXN, TRXC

Noteworthy Friday Option Activity: VRTX, AAXN, TRXC

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vertex Pharmaceuticals, Inc. , where a total of 8,194 contracts have traded so far, representing approximately 819,400 underlying shares.

Vertex Reports First-Quarter 2019 Financial Results

Vertex Reports First-Quarter 2019 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2019 and reiterated full-year 2019 financial guidance.

FDA Approves KALYDECO® (ivacaftor) As First And Only CFTR Modulator To Treat Eligible Infants With CF As Early As Six Months Of Age

FDA Approves KALYDECO® (ivacaftor) As First And Only CFTR Modulator To Treat Eligible Infants With CF As Early As Six Months Of Age

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the U.S.

Vertex Pharmaceuticals Becomes #42 Most Shorted Nasdaq 100 Component, Replacing Liberty Global

Vertex Pharmaceuticals Becomes #42 Most Shorted Nasdaq 100 Component, Replacing Liberty Global

The most recent short interest data has been released for the 04/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Vertex To Announce First-Quarter 2019 Financial Results On April 30

Vertex To Announce First-Quarter 2019 Financial Results On April 30

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close.

Vertex Appoints Charles Wagner As Chief Financial Officer

Vertex Appoints Charles Wagner As Chief Financial Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019.

Vertex Receives Approval For SYMDEKO® (tezacaftor/ivacaftor And Ivacaftor) In Australia, To Treat The Underlying Cause Of Cystic Fibrosis In People Aged 12 And Older With Certain CFTR Gene Mutations

Vertex Receives Approval For SYMDEKO® (tezacaftor/ivacaftor And Ivacaftor) In Australia, To Treat The Underlying Cause Of Cystic Fibrosis In People Aged 12 And Older With Certain CFTR Gene Mutations

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration (TGA) of Australia has granted registration to SYMDEKO ® (tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 12 years...

Two Phase 3 Studies Of The Triple Combination Of VX-445, Tezacaftor And Ivacaftor Met Primary Endpoint Of Improvement In Lung Function (ppFEV1) In People With Cystic Fibrosis

Two Phase 3 Studies Of The Triple Combination Of VX-445, Tezacaftor And Ivacaftor Met Primary Endpoint Of Improvement In Lung Function (ppFEV1) In People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the triple combination of the next-generation corrector VX-445, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function (percent...

Vertex Appoints Lloyd Carney To Its Board Of Directors

Vertex Appoints Lloyd Carney To Its Board Of Directors

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Lloyd Carney has been appointed to its board of directors as an independent director.

Positive Phase 3 Study For Tezacaftor/Ivacaftor Combination In Children Aged 6-11 Years With Cystic Fibrosis Supports European Medicines Agency Submission

Positive Phase 3 Study For Tezacaftor/Ivacaftor Combination In Children Aged 6-11 Years With Cystic Fibrosis Supports European Medicines Agency Submission

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the results of a Phase 3 study conducted in Europe and Australia of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis (CF) who have either...

Vertex Reports Full-Year And Fourth-Quarter 2018 Financial Results

Vertex Reports Full-Year And Fourth-Quarter 2018 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2018 and provided full-year 2019 financial guidance.

Health Canada Grants Market Authorization For KALYDECO® (ivacaftor) In Children Ages 12 To <24 Months With Certain Mutations In The CFTR Gene

Health Canada Grants Market Authorization For KALYDECO® (ivacaftor) In Children Ages 12 To <24 Months With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for KALYDECO ® (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to <24 months who have one of the following...

Merck KGaA, Darmstadt, Germany, Grants Exclusive License To Vertex For Two DNA Damage Response Inhibitors

Merck KGaA, Darmstadt, Germany, Grants Exclusive License To Vertex For Two DNA Damage Response Inhibitors

DARMSTADT, Germany, January 24, 2019 /PRNewswire/ -- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas    Merck KGaA, Darmstadt, Germany retains...

Vertex Announces Departure Of Ian Smith, Names Interim CFO

Vertex Announces Departure Of Ian Smith, Names Interim CFO

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ian Smith has been terminated as Chief Operating Officer and interim Chief Financial Officer (CFO) effective immediately.

Vertex To Announce Full-Year And Fourth-Quarter 2018 Financial Results On February 5

Vertex To Announce Full-Year And Fourth-Quarter 2018 Financial Results On February 5

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full year and fourth quarter 2018 financial results on Tuesday, February 5, 2019 after the financial markets close.

Vertex Announces European Commission Approval For ORKAMBI&reg; (lumacaftor/ivacaftor) For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Announces European Commission Approval For ORKAMBI® (lumacaftor/ivacaftor) For Treatment Of Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI ® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have...

Vertex And Arbor Biotechnologies Establish Collaboration To Discover Novel Proteins To Advance Discovery Of Gene-Editing Therapies

Vertex And Arbor Biotechnologies Establish Collaboration To Discover Novel Proteins To Advance Discovery Of Gene-Editing Therapies

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Arbor Biotechnologies (Arbor) today announced that the two companies have entered into a strategic research collaboration focused on the discovery of novel proteins including DNA endonucleases to...

Vertex To Present At The J.P. Morgan Healthcare Conference On January 7

Vertex To Present At The J.P. Morgan Healthcare Conference On January 7

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.

Vertex Pharmaceuticals Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Ctrip.com International

Vertex Pharmaceuticals Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Ctrip.com International

The most recent short interest data has been released for the 12/14/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Vertex Announces It Will Submit Cystic Fibrosis Medicines ORKAMBI&reg; (lumacaftor/ivacaftor) As Well As SYMKEVI&reg; (tezacaftor/ivacaftor) To Be Used In Combination With Ivacaftor, To The Scottish Medicines Consortium For Appraisal

Vertex Announces It Will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) As Well As SYMKEVI® (tezacaftor/ivacaftor) To Be Used In Combination With Ivacaftor, To The Scottish Medicines Consortium For Appraisal

Vertex Pharmaceuticals (Europe) Limited today announced that, following constructive discussions with the Scottish Government, it will submit ORKAMBI ® (lumacaftor/ivacaftor) as well as SYMKEVI ® (tezacaftor/ivacaftor) to be used in combination with...

Vertex Announces Positive Phase 2 Data In Third Proof-of-Concept Study With The NaV1.8 Inhibitor VX-150

Vertex Announces Positive Phase 2 Data In Third Proof-of-Concept Study With The NaV1.8 Inhibitor VX-150

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results of a Phase 2 study of the investigational NaV1.

Health Canada Grants Market Authorization For ORKAMBI&reg; (lumacaftor/ivacaftor) For Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Health Canada Grants Market Authorization For ORKAMBI® (lumacaftor/ivacaftor) For Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that Health Canada has granted Market Authorization for ORKAMBI ® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of...

Monday Madness: Ready to Add Some Stocks to Your Holiday Wishlist?

Monday Madness: Ready to Add Some Stocks to Your Holiday Wishlist?

Here's what you're missing on TheStreet.

Top Analysts: Five 'Strong Buy' Stocks for 2019

Top Analysts: Five 'Strong Buy' Stocks for 2019

These 5 hot stocks will deliver outsized gains in 2019, say best-performing analysts

Vertex Announces European Commission Approval For KALYDECO&reg; (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To &lt;24 Months With Certain Mutations In The CFTR Gene

Vertex Announces European Commission Approval For KALYDECO® (ivacaftor) To Treat Patients With Cystic Fibrosis Aged 12 To <24 Months With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for KALYDECO ® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at...

TheStreet Quant Rating: B (Buy)